Edgewise reports Q2 2026 results, positive Phase 2 HCM data and closed Servier sale
Edgewise plans a Phase 3 HCM trial in Q4 2026 after positive EDG-7500 data, and booked $1.55 billion upfront from its muscular dystrophy business sale to Servier.
Edgewise Therapeutics reported second quarter 2026 results on August 6, 2026, highlighting new clinical and corporate developments alongside its financials.
The company reported positive top-line results from a 12-week Phase 2 Part D CIRRUS-HCM open label trial of EDG-7500 in patients with obstructive and nonobstructive hypertrophic cardiomyopathy, a study designed to inform a future Phase 3 trial.1 Based on these results, Edgewise expects to start a Phase 3 trial in the fourth quarter of 2026.1
For its second cardiovascular candidate, EDG-15400 finished dosing in a Phase 1 study testing single and multiple ascending doses in healthy adults, evaluating safety, tolerability, pharmacokinetics and pharmacodynamics.1 The company expects to begin a Phase 2 trial in patients with heart failure with preserved ejection fraction (HFpEF) in the second half of 2026.1
On the corporate side, Edgewise completed the previously announced sale of its muscular dystrophy franchise. In July 2026, Servier acquired sevasemten and Edgewise's muscular dystrophy business for $1.55 billion upfront in cash plus up to $1.1 billion in milestone payments, for total potential consideration of up to $2.65 billion.1 The company said the deal strengthens its balance sheet, improves financial flexibility, and sharpens its focus on the cardiovascular pipeline.1 Going forward, Edgewise's pipeline now centers on "EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for heart failure with preserved ejection fraction (HFpEF) and EDG-003 for an undisclosed target," as described in the release.
On financials, cash, cash equivalents and marketable securities were about $460.7 million as of June 30, 2026, not including the $1.55 billion upfront proceeds from the Servier sale received July 10, 2026; combined, the pro forma balance was $2.0107 billion before taxes and transaction costs.1 Net loss was $57.3 million, or $0.53 per share, versus $36.1 million, or $0.34 per share, in the same period a year earlier.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.